Summary
We report the effects of ketanserin, a new 5-HT antagonist on a patient who had carcinoid syndrome with diffuse metastatic disease involving lymphatics, bone and lungs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Page, I. H., Corcoran, A. C., Underfriend, S., Sjoerdsma, A., Weissbach, H., 1955. Argentaffinoma as an endocrine tumour. Lancet i, 198–199.
Pernow, B., Walderströom, J. 1975. Determination of 5-HIAA and histamine in thirty-three cases of Carcinoid Tumor (Argentaffinoma). Am J. Med. 1, 390–395.
Page, I. H. 1958. Serotonin (5-hydroxytryptamine); the last four years. Physiol. Rev. 38, 277–335.
Cohen, M. L., Fuller, R. W., Wiley, K. S. 1981. Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle. J. Pharmacol. Exptl. Therap. 218, 421–425.
Leyssen, J. E., Awouters, F., Kennish, L., Lauron, P. M., Vanderbach, J., Janssen, P. A. J. 1981. Receptor Binding Profile of R 41 468, a novel antagonist at 5-HT2 Receptors. Life Sc. 28, 1015–1022.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sullivan, P.A., O’Donovan, M. Ketanserin, A 5 — HT antagonist, in symptomatic treatment of Carcinoid Syndrome. I.J.M.S. 155, 436 (1986). https://doi.org/10.1007/BF02940548
Issue Date:
DOI: https://doi.org/10.1007/BF02940548